Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 1NETWORK 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 28Head & Neck 14Gastrointestinal 13CNS 13Genitourinary 10Breast 9Endocrine 7Tumor-Agnostic 6Sarcoma 5Other solid neoplasm 3Gynecologic 3Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1NET 1Lymphoid 1Dermatologic 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × vandetanib × Gynecologic × Clear all
NCT00872989 2016-12-19

S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

SWOG Cancer Research Network

Phase 2 Completed
129 enrolled 17 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00862836 2016-10-10

ZACFAST

Sanofi

Phase 1/2 Terminated
15 enrolled 13 charts
Gynecologic

Ovarian Neoplasms

NCT00445549 2012-06-26

Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
12 enrolled 5 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡